Standout Papers

Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma 2020 2026 2022 2024899
  1. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma (2020)
    David A. Reardon, Alba A. Brandes et al. JAMA Oncology

Immediate Impact

4 by Nobel laureates 23 from Science/Nature 80 standout
Sub-graph 1 of 20

Citing Papers

Targeting the tumour vasculature: from vessel destruction to promotion
2024 Standout
Glioblastoma and Other Primary Brain Malignancies in Adults
2023 Standout
19 intermediate papers

Works of Surasak Phuphanich being referenced

Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma
2020 Standout
OS10.3 Randomized Phase 3 Study Evaluating the Efficacy and Safety of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: CheckMate 143
2017
and 12 more

Author Peers

Author Last Decade Papers Cites
Surasak Phuphanich 2592 1711 1282 1395 104 5.1k
Frank S. Lieberman 2434 1524 909 1455 137 4.9k
Mustafa Khasraw 1820 2211 1438 1687 193 5.6k
David M. Peereboom 2159 1645 1650 1237 196 4.6k
Bianca Pollo 2446 1293 673 1862 165 5.2k
Nicholas Butowski 3366 1355 1285 1928 186 6.1k
Antje Wick 2603 1024 949 962 85 4.4k
M. S. Mahaley 3095 1184 1929 1243 94 6.0k
W.K. Alfred Yung 3034 1349 1415 2894 107 5.8k
Juan Manuel Sepúlveda-Sánchez 1620 1463 708 1174 178 3.8k
Morris D. Groves 2458 2053 2098 1351 107 4.8k

All Works

Loading papers...

Rankless by CCL
2026